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Background
In the last years the number of melanoma patients has
increased markedly. High plasma levels of interleukin-6
(IL-6) are associated with bad prognosis and reduction
in overall survival of these patients. Statins, HMG-CoA
reductase inhibitors, are well-tolerated therapeutics for
hypercholesterolemia. We have recently shown that sim-
vastatin triggers apoptosis in 518A2 human melanoma
cells which is paralleled by concentration-dependent
changes in autocrine IL-6 secretion. Here, we investi-
gated the impact of simvastatin on the IL-6 pathway.
Methods
We investigated the expression and distribution of the
heteromeric IL-6 receptor (IL-6-R/gp130) and its down-
stream pathway in 518A2 human melanoma cells by
FACS, Western blot and real-time PCR analysis.
Furthermore, we chose a fluorescent fusion protein
(STAT3-YFP) plasmid construct to study the influence
of simvastatin on signalling down-stream of the IL-6
receptor.
Results
Increasing concentrations of simvastatin led to enhanced
surface expression of the IL-6-R and the gp130 subunit.
Cells with higher IL-6 holo-receptor expression
detached, but were still viable. In Western blot analysis
the precursor level of the less glycosylated gp130 subu-
nit was enriched in simvastatin samples, which was
hand in hand with enrichment of mature gp130 recep-
tor. The mRNA levels of IL-6-R and gp130 were not
regulated by the statin treatment. Stimulation with IL-6
of the STAT3-YFP-tranfected 518A2 cells resulted in
the formation of cytosolic density spots of STAT3-YFP,
which co-localized with lysosomal markers. Simvastatin
significantly delayed the accumulation of STAT3 in
these dots. The suppressor of cytokine signalling
(SOCS) proteins (SOCS1, SOCS3), which may play a
crucial role in the inhibition of the IL-6 pathway, were
not regulated by simvastatin on protein or mRNA level.
Conclusions
These data indicate that statins like simvastatin are cap-
able of interfering with the IL-6 pathway on the hetero-
meric IL-6 receptor, as expression is increased on the
cell surface. Furthermore, simvastatin affected the dot
formation of STAT3, which occurred significantly later
compared to the untreated cells. However, simvastatin
treatment is not able to impair the level of the negative
feed-back protein SOCS3.
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